Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia

Trial Profile

Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs RP L102 (Primary)
  • Indications Fanconi's anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2018 According to a Rocket Pharmaceuticals media release, based on the results of this study, the US FDA has ranted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to RP-L102 for the treatment of Fanconi Anemia (FA).
    • 01 Nov 2018 Long-term follow up data from the first four patients treated will be presented at American Society of Hematology 2018 Annual Meeting.
    • 01 Nov 2018 According to a Rocket Pharmaceuticals media release, Dr. Juan Bueren is a principal investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top